---
title: "The One-Vigilance® Strategic Roadmap to Corporate Excellence"
description: "Pharmacovigilance is evolving beyond compliance. New therapies, real-world data and digital innovation are changing how safety teams detect risks, protect patients and create strategic value. Discover the One-Vigilance® approach to building a more integrated, proactive and patient-centric safety strategy."
url: https://qbdgroup.com/en/whitepapers/the-one-vigilance-strategic-roadmap-to-corporate-excellence
type: "White paper"
language: en
published: 2024-11-04
publisher: "QbD Group"
citation: "QbD Group, \"The One-Vigilance® Strategic Roadmap to Corporate Excellence\", https://qbdgroup.com/en/whitepapers/the-one-vigilance-strategic-roadmap-to-corporate-excellence"
---
# The One-Vigilance® Strategic Roadmap to Corporate Excellence
> Pharmacovigilance is evolving beyond compliance. New therapies, real-world data and digital innovation are changing how safety teams detect risks, protect patients and create strategic value. Discover the One-Vigilance® approach to building a more integrated, proactive and patient-centric safety strategy.

The **drug safety landscape** is changing rapidly. Increasingly complex **biopharmaceutical products**, **growing data volumes**, **advanced technologies** and greater **patient involvement** are pushing pharmacovigilance teams to rethink traditional approaches to **safety monitoring and risk management**.

This white paper introduces QbD Group's **One-Vigilance® concept**: a **unified and centralized approach** designed to **connect the critical elements of pharmacovigilance** and **streamline drug safety activities** across the **product lifecycle**. It explores how safety teams can move beyond **regulatory compliance** and align pharmacovigilance with **innovation, business strategy, technology and patient needs**.

You'll also discover how **real-world data, digital health technologies and advanced analytics** can support more **proactive and patient-centric vigilance**, and how a **strategic approach to sourcing and centralization** can help organizations improve **efficiency** while maintaining **global and local compliance**.

## Key Takeaways

- **Understand the Changing Drug Safety Landscape.** Explore how regulatory change, advanced technologies, growing data volumes, globalization and patient-centric approaches are reshaping pharmacovigilance.

- **Discover the One-Vigilance® Vision.** Learn how a unified, centralized approach can connect patients, products and adverse events while bringing greater integration to pharmacovigilance activities.

- **Navigate Safety Across New Biopharmaceutical Products.** Understand the specific pharmacovigilance challenges associated with ATMPs, biotech products and precision medicine, and why emerging therapies require increasingly adaptable safety strategies.

- **Put Patients and Real-World Data at the Center.** Discover how wearables, digital health solutions and RWD can provide richer insights into patient experiences, support earlier safety signal detection and strengthen proactive risk management.

- **Use Advanced Analytics to Strengthen Vigilance.** Explore how AI, machine learning and advanced analytics can help identify safety trends and signals in large datasets, enabling earlier detection and more timely intervention.

- **Turn Pharmacovigilance Into a Strategic Value Driver.** Learn how centralization, strategic sourcing and the right balance between internal resources and external expertise can improve efficiency while maintaining patient safety and regulatory compliance.
---
Source: https://qbdgroup.com/en/whitepapers/the-one-vigilance-strategic-roadmap-to-corporate-excellence — © QbD Group. Quote freely with attribution and a link back.